Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review

<i>ROS1</i> gene rearrangements define a distinct molecular subtype of non-small cell lung cancer (NSCLC), occurring in approximately 2% of cases and frequently associated with younger age, non-smoker status, and a high incidence of brain metastases. The discovery of ROS1 as an oncogenic driver has...

Полное описание

Библиографические подробности

Главные авторы:	Hervé Bischoff, Sébastien Gendarme, Laura Somme, Christos Chouaid, Roland Schott
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2025-11-01
Серии:	Current Oncology
Предметы:	ROS1 non-small cell lung cancer tyrosine kinase inhibitor resistance mutations brain metastases targeted therapy
Online-ссылка:	https://www.mdpi.com/1718-7729/32/11/626
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!